Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of trastuzumab deruxtecan combinations versus carboplatin + paclitaxel + pembrolizumab in HER2-expressing pMMR endometrial cancer
NL-OMON60661Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab deruxtecan, rilvegostomig, pembrolizumab, carboplatin and paclitaxel in endometrial cancer (EC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival by BICR. Planned start Sep 2025; status: withdrawn.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON60661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60661.